P

Utilizziamo cookie essenziali, di analisi e pubblicitari per migliorare l'esperienza, misurare l'utilizzo e ottimizzare le campagne.

Maggiori informazioni su Informativa sulla privacy · Termini di Servizio · Cookie Policy

Salva

Pending

HORIZON-HLTH-2027-01-DISEASE-05International

Pending

Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential

Horizon Europe

Description

Europe

Health & Life Sciences•100% • 44.2M€

Pending

Dates & Deadlines

Publication Date

Not defined

Opening Date

October 29, 2026

Application Phases

Fase única

February 17, 2027 at 05:00 PM

Financial Details

Non-Refundable

Maximum Funding Rate

100%

Budget

44.2M€

Eligible Project Value

9M€ - 11M€

Criteria & Documents

Eligible Expenses

●Personnel Costs
●Travel costs
●Equipment costs
●Other goods, works and services costs
●Subcontracting
●Indirect Costs
●Personnel
●Research infrastructure
●Equipment
●Consumables
●Travel
●Dissemination activities

Access Conditions

●Legal entities from EU Member States and Associated Countries
●Consortium must include partners from at least three different EU Member States or Associated Countries
●Compliance with general and specific admissibility and eligibility criteria
●Project proposals must comply with restrictions on participation by legal entities from China for RIAs and IAs under this destination
●Entities identified as high-risk suppliers of mobile network communication equipment are ineligible for projects subject to network security restrictions

Selection Criteria

●Excellence (scientific and technical merit)
●Impact (contribution to policy and partnership KPIs)
●Quality and efficiency of implementation
●Scientific and technical excellence
●Impact on disease burden reduction
●Contribution to EU policy priorities

Mandatory Information

●Application form (Part A and Part B)
●Budget
●Administrative forms
●Technical annex/Project description
●Consortium agreement (if applicable)
●Budget breakdown
●Ethics self-assessment

Result Indicators

●Reduction in disease burden (DALYs)
●Strengthened Research and Innovation capacity
●Adoption of innovative approaches in healthcare
●Cross-border health threat reduction

EU Programme Details

Call ID: HORIZON-HLTH-2027-01-DISEASE-05
Cluster: Health
Destination: D3. Tackling diseases and reducing disease burden
Submission Mode: Single-stage
EU Contribution: Around €10,000,000.00 to €11,000,000.00 per project
Expected Projects: 5 projects
Funding Rate Rule: Up to 100% of eligible costs for Research and Innovation Actions (RIA)

Salva

Pending

HORIZON-HLTH-2027-01-DISEASE-05International

Pending

Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential

Horizon Europe

Description

Europe

Health & Life Sciences•100% • 44.2M€

Pending

Dates & Deadlines

Publication Date

Not defined

Opening Date

October 29, 2026

Application Phases

Fase única

February 17, 2027 at 05:00 PM

Financial Details

Non-Refundable

Maximum Funding Rate

100%

Budget

44.2M€

Eligible Project Value

9M€ - 11M€

Criteria & Documents

Eligible Expenses

●Personnel Costs
●Travel costs
●Equipment costs
●Other goods, works and services costs
●Subcontracting
●Indirect Costs
●Personnel
●Research infrastructure
●Equipment
●Consumables
●Travel
●Dissemination activities

Access Conditions

●Legal entities from EU Member States and Associated Countries
●Consortium must include partners from at least three different EU Member States or Associated Countries
●Compliance with general and specific admissibility and eligibility criteria
●Project proposals must comply with restrictions on participation by legal entities from China for RIAs and IAs under this destination
●Entities identified as high-risk suppliers of mobile network communication equipment are ineligible for projects subject to network security restrictions

Selection Criteria

●Excellence (scientific and technical merit)
●Impact (contribution to policy and partnership KPIs)
●Quality and efficiency of implementation
●Scientific and technical excellence
●Impact on disease burden reduction
●Contribution to EU policy priorities

Mandatory Information

●Application form (Part A and Part B)
●Budget
●Administrative forms
●Technical annex/Project description
●Consortium agreement (if applicable)
●Budget breakdown
●Ethics self-assessment

Result Indicators

●Reduction in disease burden (DALYs)
●Strengthened Research and Innovation capacity
●Adoption of innovative approaches in healthcare
●Cross-border health threat reduction

EU Programme Details

Call ID: HORIZON-HLTH-2027-01-DISEASE-05
Cluster: Health
Destination: D3. Tackling diseases and reducing disease burden
Submission Mode: Single-stage
EU Contribution: Around €10,000,000.00 to €11,000,000.00 per project
Expected Projects: 5 projects
Funding Rate Rule: Up to 100% of eligible costs for Research and Innovation Actions (RIA)